|
How and where to order Lithium Carbonate (Eskalith, Lithobid) 150 mg, 300 mg, 400 mg tablets or capsules online on the Advancing Suicide Prevention Magazine website:
Shop: | PHARMA SHOP - 10% discount coupon hf-5478
|
Sellers: | LITHIUM STORES
|
Prices: | from $0.26 per pill
|
Forms: | Lithium 150 mg, 300 mg, 400 mg capsules or tablets
|
Quantity: | 30-360 pills
|
Type: | Lithium Carbonate brand, Eskalith generic, Lithobid generic
|
Payment: | Visa, Mastercard, AmEx, Bitcoin
|
Delivery: | Regular and express mail service
|
Shipping: | Worldwide, including USA, UK, Europe, Canada, Australia |
Indications and usage:
Eskalith and Lithobid (Lithium Carbonate) as psychoactive drugs are indicated in the treatment of psychiatric, mental and mood medical conditions in patients 7 years and older such as bipolar disorder, depression, schizophrenia, manic episodes of manic-depressive illness, to reduce the risk of suicide. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania.
Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness and possibly hostility. When given to a patient experiencing a manic episode, this medication may produce a normalization of symptomatology within 1 to 3 weeks.
Dosage and administration:
Recommended starting dosage for adults and pediatric patients over 30 kg: 300 mg tablets or capsules, three times daily.
Recommended starting dosage for pediatric patients 20 to 30 kg: 300 mg tablets or capsules twice daily.
Obtain serum lithium concentration assay after 3 days, drawn 12 hours after the last oral dose and regularly until patient is stabilized.
Acute manic or mixed episodes (patients 7 years and older): titrate to serum lithium concentrations 0.8 to 1.2 mEq/L.
Maintenance treatment for bipolar I disorder (patients 7 years and older): titrate to serum lithium concentrations 0.8 to 1 mEq/L.
Pre-treatment screening: evaluate renal function, vital signs, electrolytes, thyroid function, concurrent medications, and pregnancy status.
Mild to moderate renal impairment (CLer 30 to 89 mL/min): start with dosages less than those for patients with normal renal function, titrate slowly with frequent monitoring.
Severe renal impairment (CLer < 30mL/min): avoid use of lithium.
Dosage forms and strengths:
Capsules: 150 mg, 300 mg, 600 mg of lithium carbonate.
Tablets: 150 mg, 250 mg, 300 mg, 400 mg of lithium carbonate.
Tablets, extended release: 200 mg, 300 mg, 400 mg, 450 mg of lithium carbonate.
Tablets, controlled release: 300 mg, 450 mg of lithium carbonate.
Oral solution: 8 mEq of lithium (Li+) per 5mL.
Overdosage:
The toxic concentrations for lithium (>= 1.5 mEq/L) are close to the therapeutic concentrations. It is therefore important that patients and their families be cautioned to watch for early toxic symptoms and to
discontinue the drug and inform the physician should they occur.
Treatment
No specific antidote for lithium poisoning is known. Treatment is supportive. Early symptoms of lithium toxicity can usually be treated by reduction or cessation of dosage of the drug and resumption of the treatment at a lower dose after 24 to 48 hours. In severe cases of lithium poisoning, the first and foremost goal of treatment consists of elimination of this ion from the patient.
Treatment is essentially the same as that used in barbiturate poisoning: 1) gastric lavage, 2) correction of fluid and electrolyte imbalance and, 3) regulation of kidney functioning. Urea, mannitol, and aminophylline all produce significant increases in lithium excretion. Hemodialysis is an effective and rapid means of removing the ion from the severely toxic patient. However, patient recovery may be slow.
Infection prophylaxis, regular chest X-rays, and preservation of adequate respiration are essential.
Contraindications:
Known hypersensitivity to any inactive ingredient in this medication.
Warnings and precautions:
Lithium-induced polyuria: may develop during initiation of treatment. Increases risk of lithium toxicity. Educate patient to avoid dehydration. Monitor for lithium toxicity and metabolic acidosis. Discontinue lithium or treat with amiloride as a therapeutic agent.
Hyponatremia: symptoms are more severe with faster-onset hyponatremia. Dehydration from protracted sweating, diarrhea, or elevated temperatures from infection increases risk of hyponatremia and lithium toxicity. Educate patients on maintaining a normal diet with salt and staying hydrated. Monitor for and treat hyponatremia and lithium toxicity, which may necessitate a temporary reduction or cessation of lithium and infusion of serum sodium.
Lithium-induced chronic kidney disease: associated with structural changes in patients on chronic lithium therapy. Monitor kidney function during treatment with lithium.
Encephalopathic syndrome: increased risk in patients treated with lithium and an antipsychotic. Monitor routinely for changes to cognitive function.
Hypothyroidism and hyperthyroidism: monitor thyroid function regularly.
Hypercalcemia and hyperparathyroidism: associated with long-term lithium use. Monitor serum calcium.
Adverse reactions, side effects:
Common adverse reactions of medicines containing lithium carbonate:
Adult patients: fine hand tremor, polyuria, mild thirst, nausea, general discomfort during initial treatment.
Pediatric patients (7-17 years): nausea, vomiting, polyuria, thyroid abnormalities, tremor, thirst/polydipsia, dizziness, rash/dermatitis, ataxia/gait disturbance, decreased appetite, and blurry vision.
To report suspected adverse reactions of your lithium drug, contact its manufacturer, distributor, or your local FDA.
Drug interactions:
Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. Recommend frequent monitoring of serum lithium concentration and adjust dosage when necessary.
Serotonergic agents: increased risk of serotonin syndrome when co-administered with lithium containing medications.
Antipsychotics: there have been reports of neurologic adverse reactions in patients treated with lithium and an antipsychotic, ranging from extrapyramidal symptoms to neuroleptic malignant syndrome.
Related medications:
Alprazolam 1 mg tablets
Clozapine (Clozaril)
Use in specific populations:
Pregnancy
May cause fetal and/or neonatal harm.
Lactation
Discontinue breastfeeding if a breastfed infant develops lithium toxicity.
Pediatric use
The safety and effectiveness of lithium has not been established in pediatric patients less than 7 years of age with bipolar I disorder.
Geriatric use
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Renal impairment
Use caution during dose selection, starting with dosages less than those for patients with normal renal function while carefully monitoring for side effects.
Patient counseling information:
Dosage and administration
Advise patients that lithium is a mood stabilizer, and should only be taken as directed. Emphasize the importance of compliance with the prescribed treatment and to not adjust the dose of lithium without first consulting their healthcare provider. Inform patients that they will need to have regular blood draws to determine if their dose of lithium is appropriate.
Instruct patients not to double the dose if a dose is missed, due to the complexity of individualized dosing and potential for lithium toxicity.
Lithium toxicity
Inform patients on adverse reactions related to lithium toxicity that require medical attention. Advise patients to discontinue lithium treatment and contact their healthcare provider if clinical signs of lithium toxicity such as diarrhea, vomiting, tremor, lack of muscle coordination, drowsiness, abnormal heart rhythm or muscular weakness occur.
Lithium-induced polyuria
Counsel patients on the adverse reactions related to lithium-induced polyuria, when to seek medical attention, and the importance of maintaining normal diet with salt and staying hydrated.
Hyponatremia
Counsel patients on the adverse reactions of hyponatremia, when to seek medical attention, the importance of maintaining a normal diet including adequate salt intake and staying hydrated. Salt supplements
and additional fluids may be required if excessive losses occur.
Serotonin syndrome
Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of lithium with other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, St. John's Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid).
Drug interactions
Advise patients that many drugs can interact with lithium and to inform their doctor and pharmacist if they are taking any over the counter medication, including herbal medication, or are started on a new prescription.
Somnolence
Tell patients that lithium may cause somnolence particularly when initiating treatment and to be cautious about operating vehicles or hazardous machinery, until they are reasonably certain that lithium treatment does not affect them adversely.
Pregnancy
Advise pregnant women of the potential risk to a fetus and/or neonate.
Lactation
Advise women that breastfeeding is not recommended during treatment with lithium medications.
Where to buy lithium carbonate online:
To purchase Lithobid, Eskalith (Lithium Carbonate) 150 mg, 300 mg, 400 mg tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.
Here is a list of popular medications containing lithium carbonate as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
Trade name of the drug |
Pharmaceutical forms and doses |
Companies |
Eskalith |
Capsules; Oral; Lithium Carbonate 300 mgTablets; Oral; Lithium Carbonate 300 mg |
GlaxoSmithKline |
Eskalith CR |
Tablets, Extended Release; Oral; Lithium Carbonate 450 mg |
GlaxoSmithKline |
Lithobid |
Tablets, Extended Release; Oral; Lithium Carbonate 300 mg |
ANI PharmaceuticalsJDS PharmaceuticalsNoven PharmaceuticalsSolvay |
Lithosun |
Tablets; Oral; Lithium Carbonate 250 mg, 300 mg |
Sun Pharmaceutical IndustriesApotheca Marketing |
Priadel |
Syrup; Oral; Lithium Carbonate 200 mg / 5 mlTablets, Prolonged Release; Oral; Lithium Carbonate 200 mg, 400 mg |
Sanofi-Aventis3MW. M. Bamford & Co. |
Quilonum SR |
Tablets; Oral; Lithium Carbonate 450 mg |
GlaxoSmithKline |
Home | About Us | Editorial Advisory Board | Testimonials | Issues | Advertise | Subscribe | Contact Us
Copyright © 2006 - 2023 Point de Vue Communications, Inc. All rights reserved.
|
|
|